

In the claims:

Kindly amend the claims as follows:

1. (Amended) A controlled release formulation of erythromycin A or a [derivatives] derivative thereof, suitable for once daily administration, comprising [a pharmaceutically effective amount of] erythromycin from about 66% w/w to about 90% w/w of the total tablet weight and from about 0.1% to about 4% w/w of one or more pharmaceutically acceptable rate controlling polymers.

Please delete claims 3 and 4.

11. (Amended) A monolithic controlled release formulation of clarithromycin comprising [100-]1000 mg of clarithromycin, wherein the total weight of the dosage unit is not more than 1500 mg.
12. (Amended) A process for the preparation of a controlled release formulation of erythromycin A or a derivative thereof suitable for once daily administration comprising mixing [a pharmaceutically effective amount of] erythromycin or a derivative thereof in an amount from about 66% w/w to about 90% w/w of the total tablet